Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection

BACKGROUND: Although the incidence of Clostridium difficile infection (CDI) is increasing, available CDI treatment options are limited in terms of sustained response after treatment. This phase 3 trial assessed the efficacy and safety of surotomycin, a novel bactericidal cyclic lipopeptide, versus o...

Descripción completa

Detalles Bibliográficos
Autores principales: Boix, Vicente, Fedorak, Richard N., Mullane, Kathleen M., Pesant, Yves, Stoutenburgh, Uschi, Jin, Mandy, Adedoyin, Adedayo, Chesnel, Laurent, Guris, Dalya, Larson, Kajal B., Murata, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414029/
https://www.ncbi.nlm.nih.gov/pubmed/28480267
http://dx.doi.org/10.1093/ofid/ofw275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414029/
https://www.ncbi.nlm.nih.gov/pubmed/28480267
http://dx.doi.org/10.1093/ofid/ofw275

Ejemplares similares